Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care.
We reviewed duration of illness in 26 children with severe pediatric Guillain-Barré syndrome (GBS) during two contiguous 8-year periods that represent a "non-treatment era" of supportive care alone or a "treatment era" of supportive care plus either plasma exchange or intravenous immunoglobulin intervention. Our findings of similar recovery times in each treatment group suggest that immunotherapy in severe pediatric GBS may be less effective than in adult GBS, or effective only when given to certain patients very early in the course of the illness.
Graf
W D
WD
Department of Pediatrics, University of Washington, Seattle, USA.
Katz
J S
JS
Eder
D N
DN
Smith
A J
AJ
Chun
M R
MR
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007223:Infant; D008297:Male; D010166:Palliative Care; D010951:Plasma Exchange; D011129:Polyradiculoneuropathy / Q000503:physiopathology* / Q000628:therapy*; D011379:Prognosis